article thumbnail

Gene editing: beyond the hype

pharmaphorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Maybe in 50 years’ time we’ll be using gene editing to lower cholesterol, but it won’t replace statins in anyone but those with life threatening mutations for a long time”. Zinc fingers.

article thumbnail

Delivering on the promise of gene editing

Drug Discovery World

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The FDA’s Guidance on Gene Edited Foods + What American Foods are Banned in Other Countries? – Xtalks Food Podcast Ep. 149

XTalks

In a pivotal move for the food industry, the US Food and Drug Administration (FDA) has unveiled industry guidance for genome edited foods derived from plants. Genome editing stands as a cutting-edge technique that ingeniously introduces new traits into plants.

article thumbnail

STAT+: At genome-editing summit, experts worry that rule changes on embryo research in China fall short

STAT News

LONDON — The first gene-edited children were born in China five years ago , but it’s unlikely to happen again there anytime soon. That was the message Chinese scientists delivered Monday on the opening day of the Third International Summit on Human Genome Editing in London.

Genome 98
article thumbnail

Gene-edited babies: Current techniques not safe, say experts

The Pharma Data

Current scientific techniques are not yet safe or effective enough to be used to create gene-edited babies, an international committee says. The world’s first gene-edited babies were born in China in November 2018. Why is gene-editing babies controversial? The committee was set up in response.

article thumbnail

Revvity opens Scientific Centre of Excellence for genomics

Drug Discovery World

The centre also features a newly built demo lab which will bring the Revvity portfolio closer to scientists.

Genome 52
article thumbnail

eGenesis raises US$125m in Series C financing to ‘transform’ transplant medicine

BioPharma Reporter

The gene-editing and genome-engineering company, eGenesis, today announced the completion of a US$125m Series C financing round.